Skip to main content
AbClon Inc. logo

AbClon Inc. — Investor Relations & Filings

Ticker · 174900 ISIN · KR7174900001 KO Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-11-11 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 174900

About AbClon Inc.

https://www.abclon.com/en/

AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '앱클론(주)' (AbClon Inc.) covering the period from 2021-01-01 to 2021-09-30. It contains detailed financial statements, management discussion, and corporate governance information, which is characteristic of a comprehensive interim/quarterly financial report. It is not a mere announcement or certification, as it includes substantive financial data and business analysis. 9M 2021
2021-11-11 Korean
기타경영사항(특허권취득)(자율공시)(안정성이 개선된 HER2에 특이적으로 결합하는 항체)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a HER2-specific antibody by AbClon. It details the patent name, content, holder, and utilization plan. Since it does not fit into specific categories like financial reports, dividends, or management changes, and is a standard regulatory disclosure of corporate activity, it falls under the general regulatory filing category.
2021-10-29 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company AbClon Inc. (앱클론 주식회사) for the period covering January 1, 2021, to June 30, 2021. It contains comprehensive financial statements, management discussion, and operational details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-13 Korean
투자판단관련주요경영사항(재발성 또는 불응성 B세포 비호지킨 림프종 환자에서 AT101 (항-CD19 키메릭항원수용체 T세포)의 안전성, 내약성 및 유효성을 평가하기 위한 공개, 단일군, 다기관, 제1/2상 국내 임상시험계획 (IND) 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (AbClon) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a clinical trial. Since this is a specific regulatory announcement regarding clinical trial progress and does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate announcements.
2021-06-24 Korean
[기재정정]사업보고서 (2020.12)
Regulatory Filings Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Annual Report' (사업보고서). It explicitly lists the sections being corrected (e.g., dividend policy, articles of incorporation, use of funds, and management status) and provides the 'before' and 'after' content for these sections. Since this is a formal amendment to an existing Annual Report filed with the Korean financial authorities (Financial Supervisory Service/KRX), it falls under the category of regulatory filings that update or correct previously submitted financial reports. FY 2020
2021-06-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. It also mentions that the actual IR presentation materials will be distributed at the event or available on the KRX KIND system. Since this is an announcement of an event rather than the presentation deck itself, and it fits the criteria for a regulatory filing regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2021-05-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.